Primary mediastinal (thymic) large B-cell lymphoma

What changed: Primary mediastinal (thymic) large B-cell lymphoma

Cancer page →

Every dated change on the records linked to Primary mediastinal (thymic) large B-cell lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result4Milestone8This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordPrimary mediastinal (thymic) large B-cell lymphoma
Facts on this page last checked
When this page itself was last checked or edited.

2024 · 2

2022 · 1

2022Trial resultTRANSFORM
TRANSFORM reported
EFS HR 0.

2021 · 1

2021Trial resultZUMA-7
ZUMA-7 reported
EFS HR 0.

2019 · 2

2018 · 1

2018MilestonePembrolizumab
Pembrolizumab approved for relapsed or refractory disease after KEYNOTE-170
A milestone in how this cancer is treated.

2017 · 1

2017MilestoneAxicabtagene ciloleucel
Axicabtagene ciloleucel approved for large B-cell lymphoma, including primary mediastinal disease
A milestone in how this cancer is treated.

2013 · 1

2013MilestoneRituximab
Dunleavy: dose-adjusted EPOCH-R cures 93 percent without radiotherapy (NEJM)
A milestone in how this cancer is treated.

2003 · 1

2003MilestoneHodgkin lymphoma
Gene expression profiling shows its kinship with classical Hodgkin lymphoma and the 9p24.1 lesion
A milestone in how this cancer is treated.

2001 · 1

2001MilestoneNon-Hodgkin lymphoma (all types)
WHO classification lists primary mediastinal large B-cell lymphoma as a separate entity
A milestone in how this cancer is treated.

1980 · 1

1980MilestonePrimary mediastinal (thymic) large B-cell lymphoma
Mediastinal large B-cell lymphoma of thymic origin first described as a distinct clinical entity
A milestone in how this cancer is treated.